Methylethylpyridinol in ophthalmology: Mechanisms of action and clinical results

Methylethylpyridinol is a frequently used drug in ophthalmology. Many years of experience of its use in clinical practice and a variety of pharmacological effects have caused its wide introduction in the treatment of a wide range of ophthalmopathologies, as well as in various fields of medicine. It is known that methylethylpyridinol has antioxidant activity, neuroprotective effect, ability to stabilize cell membranes and improve microcirculation. These properties open wide possibilities for its application in therapy of eye diseases, in which oxidative stress and deterioration of blood supply play a key role. The broad spectrum of action of methylethylpyridinol is useful in combination therapy with other drugs, which allows to achieve a synergistic and enhanced therapeutic effect. This, in turn, can be applied for treatment of various diseases, including ophthalmologic pathology of the anterior and posterior segment of the eye, as well as ocular manifestations of systemic diseases. A significant advantage of methylethylpyridinol is the presence of the form of eye drops, which has an equivalent effect in comparison with parabulbar administration of the drug. This determines the unique position of the drug in the form of eye drops in ophthalmopharmacotherapy, because to date, the pharmaceutical market has no alternative agents with such a wide range of pharmacological properties in a convenient and safe dosage form, targeting the structures of the eye. This review discusses the therapeutic properties of methylethylpyridinol and the results of preclinical and clinical studies of this drug, which is important for expanding the prospects of its clinical application and ensuring patient safety.

1. Munz IV, Direev AO, Gusarevich OG, Shcherbakova LV, Mazdorova EV, Malyutina SK. Prevalence of ophthalmic diseases in the population older than 50 years. Vestnik Oftalmologii. 2020;136(3):106–115. (In Russ.) https://doi.org/10.17116/oftalma2020136031106.

2. Prikhodko VA, Okovityi SV. Possibilities and prospects for antioxidant therapy in ocular diseases. Meditsinskiy Sovet. 2022;16(23):263–273. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-23-263-273.

3. Novikov VE, Kovaleva LA, Losenkova SO, Klimkina EI. Pharmacology of antioxidants based on 3-hydroxypyridine. Vestnik of Smolensk State Medical Academy. 2004;(3):69–77. (In Russ.) Available at: https://sgma.info/ru/issues-archive/2000-2009/2004/2004-3.html.

4. Lisovskaya MV, Kvasyuk EI. Synthesis of esters of emoxypine. Journal of the Belarusian State University. Ecology. 2018;(4):119–127. (In Russ.) Available at: https://elib.bsu.by/bitstream/123456789/217620/1/119-127.pdf.

5. Gupta DS, Bagwe Parab S, Kaur G. Promising effects of emoxypine and its succinate derivative in the management of various diseases-with insights on recent patent applications. Curr Res Pharmacol Drug Discov. 2022;3:100121. https://doi.org/10.1016/j.crphar.2022.100121.

6. Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(4):115–124. (In Russ.) https://doi.org/10.17116/jnevro2019119041115.

7. Volchegorskii IA, Miroshnichenko IYu, Rassohina LM, Faizullin RM. Experimental study of 3-oxypiridine and succinic acid derivates antidepressant activity in mice. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2013;76(7):6–10. (In Russ.) Available at: http://www.ekf.folium.ru/index.php/ekf/article/view/88.

8. Volchegorskii IA, Miroshnichenko IY, Rassokhina LM, Faizullin RM, Malkin MP, Pryakhina KE, Kalugina AV. Comparative analysis of the anxiolytic effects of 3-hydroxypyridine and succinic acid derivatives. Bulletin of Experimental Biology and Medicine. 2015;158(6):756–761. https://doi.org/10.1007/s10517-015-2855-3

9. Volchegorskii IA, Tur EV, Solyannikova OV, Rykun VS, Sumina MS, Dmitrienko VN, Berdnikova EV. Effectiveness of 3-hydroxypyridine and succinic acid derivatives in complex treatment of primary open-angle glaucoma. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2012;75(7):20–26. (In Russ.) Available at: http://www.ekf.folium.ru/index.php/ekf/article/view/184.

10. Babizhayev MA, Bunin AYa. Lipid peroxidation in open-angle glaucoma. Acta Ophthalmol. 1989;67(4):371–377. https://doi.org/10.1111/j.1755-3768.1989.tb01617.x

11. Yanovskaya NP, Shtol’ko VN, Burlakova EB. Effect of low-dose emoxypine and pyridoxine hydrochloride on human cataract and glaucoma. Bulletin of Experimental Biology and Medicine. 1993;115(5):517–520. https://doi.org/10.1007/BF00784176.

12. Loznikova SG, Sukhodola AA, Shcharbina NYu, Shcharbin DG. The effects of magnesium, acetylsalicylic acid, and emoxypine on platelet aggregation. Biophysics. 2014;59(6):900–903. https://doi.org/10.1134/S0006350914060098.

13. Gromova ОА, Torshin IYu, Gromov АN. Chemoreactome analysis of methylethylpyridinol and possible mechanisms of ophthalmoprotection. Meditsinskiy Sovet. 2024;18(23):189–198. (In Russ.) https://doi.org/10.21518/ms2024-547.

14. Dautova ZA, Mitrofanova NV. The use of the drug Emoksipin in the complextreatment of glaucoma. Practical Medicine. 2016;(2-1):153–159. (In Russ.) Available at: https://pmarchive.ru/primenenie-preparata-emoksipinv-kompleksnom-lechenii-glaukomy/.

15. Stolyarova VV. The effect of emoxypine on the electrical instability of myocardium and the parameters of homeostasis in patients with acute disturbance of cerebral circulations. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2002;65(3):13–15. (In Russ.) Available at: http://www.ekf.folium.ru/index.php/ekf/article/view/1520.

16. Gatsura VV, Smirnov LD. Cardioprotective properties of some synthetic antioxidants. Pharmaceut Chem J. 1993;26(11-12):795–802. https://doi.org/10.1007/BF00767648.

17. Konorev EA, Polumiskov VI, Avilova OA, Golikova AP. Emoxipin in reperfusion of ischemic myocardium in dogs: effects on infarct size and plasma creatine kinase activity. Bulletin of Experimental Biology and Medicine. 1990;110(9):252–254. (In Russ.) Available at: https://pubmed.ncbi.nlm.nih.gov/2268707/.

18. Шевченко ОП, Праскурничий ЕА, Яхно НН, Парфенов ВА. Артериальная гипертония и церебральный инсульт. М.: Реафарм; 2001.

19. Boldina N.V., Mikhin V.P., Chernyatina M.A. Effectiveness of some cardiac cytoprotectors in patients with arterial hypertension complicated by acute ischemic stroke. Effective Pharmacotherapy. Cardiology and Angiology. 2008;(2):18–23. (In Russ.) Available at: https://umedp.ru/upload/iblock/c98/mexikor.pdf

20. Torshin IYu, Gromova OA, Sardaryan IS, Fedotova LE. Comparative chemoreactome analysis of mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(1-2):75−83. (In Russ.) https://doi.org/10.17116/jnevro20171171275-84.

21. Litvinenko IV, Krasakov IV, Bisaga GN, Skulyabin DI, Poltavsky ID. Current concepts in the pathogenesis of neurodegenerative diseases and treatment strategies. Modern conception of the pathogenesis of neurodegenerative diseases and therapeutic strategy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(6-2):3−10. (In Russ.) https://doi.org/10.17116/jnevro2017117623-10.

22. Barnham KJ, Colin L, Masters BAI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3(3):205–214. https://doi.org/10.1038/nrd1330.

23. Imam M, Zhang SM, Ma J, Wang H, Wang F. Antioxidants Mediate Both Iron Homeostasis and Oxidative Stress. Nutrients. 2017;9(7):671. https://doi.org/10.3390/nu9070671.

24. Zorkina AV, Prosvirina ON. The effect of rubomycin, mexidol and emoxypine on some metabolic indexes and the proccess of spontaneous metastasis under conditions of experimental neoplasia. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2007;70(1):57−59. (In Russ.) Available at: http://www.ekf.folium.ru/index.php/ekf/article/view/879.

25. Sologub AA, Akberova SI, Ziangirova GG. Emoxipine as an inhibitor of angiogenesis. Bulletin of Experimental Biology and Medicine. 1992;114(12):620–622. (In Russ.) Available at: https://pubmed.ncbi.nlm.nih.gov/1284038/.

26. Kurysheva AP, Kidraleeva SR. Treatment of hypoxemic changes of cornea at patients with contact correction of sight. Eye. 2014;(6):13−17. (In Russ.) Available at: http://emoxypin.ru/sites/default/files/gipoksiya_rogovicy.pdf.

27. Razgulin AS, Zhdanovich IV, Stolyarova VV, Lapshin RD, Lobach AR. substantiation of complex therapy “dry eye” syndrome according to pharmacoeconomic analysis and experimental model. Ural Medical Journal. 2016;(11):46–50. (In Russ.) Available at: https://elibrary.ru/xfwopp.

28. Arkhipova LT, Dolgova IG. Prognostic significance of local and systemic indicators of lipid peroxidation and antioxidant system in perforating wounds of the eyes and their time course during local antioxidant treatment. Vestnik Oftalmologii. 2001;117(5):37–40. (In Russ.) Available at: https://pubmed.ncbi.nlm.nih.gov/11765467/.

29. Kvasha OI, Chesnokova NB. Nitric oxide and emoxipin in the treatment of burn ischemia of conjunctiva (experimental studies). Bioradikaly i Antioksidanty. 2016;(3):204–205. (In Russ.) Available at: https://elibrary.ru/zurhlt.

30. Нероев ВВ, Гундорова РА, Макаров ПВ (ред.). Ожоги глаз. М.: ГЭОТАРМедиа; 2013. 223 с.

31. Chesnokova NB, Beznos OV, Pavlenko TA, Zabozlaev AA, Pavlova MV. Effects of hydroxypyridine derivatives mexidol and emoxypin on the reparative processes in rabbit eye on the models of corneal epithelial defect and conjunctival ischemia. Bulletin of Experimental Biology and Medicine. 2014;158(9):332–335. (In Russ.) Available at: https://elibrary.ru/smnwbd.

32. Аксенова ОА, Аксенова СВ, Куликова МП. Влияние эмоксипина на некоторые показатели системы иммунитета при герпетических кератитах. В: Тахчиди ХП (ред.). Актуальные проблемы офтальмологии: материалы VI Всероссийской научной конференции молодых ученых. Москва, 21 июня 2011 г. М.; 2011. Режим доступа: https://eyepress.ru/article.aspx?9186.

33. Курышева НИ. Глаукомная оптическая нейропатия. М.: МЕДпресс-информ; 2006. 136 с.

34. Антонов АА, Астахов СЮ, Борзунов ОИ, Борзунова НС, Брежнев АЮ, Бржеский ВВ и др. Глаукома первичная открытоугольная: клинические рекомендации. М.; 2024. 91 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/96_2.

35. Антонов АА, Астахов СЮ, Брежнев АЮ, Бржеский ВВ, Газизова ИР, Голубев СЮ и др. Глаукома первичная закрытоугольная: клинические рекомендации. М.; 2024. 76 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/631_2.

36. Sinitskii AI, Kochkina OT, Grobovoi SI. Influence of 2-ethyl-6-methyl-3-hydr oxypyridine on the functional state of rat liver mitochondria in vitro. Pharmaceutical Chemistry Journal . 2021;55(1):8–12. (In Russ.) https://doi.org/10.30906/0023-1134-2021-55-1-8-12.

37. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2012;112(12):86–90. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologiii-psikhiatrii-im-s-s-korsakova/2012/12/031997-729820121215.

38. Крутенков ОА, Евграфов ВЮ. Влияние эмоксипина и препаратов тромболитического ряда на состояние зрительных функций у больных диабетической ретинопатией. В: Материалы II Евро-Азиатской конференции по офтальмохирургии. Екатеринбург, 25–28 апреля 2001 г. Екатеринбург; 2001. Ч. 2. С. 326–327.

39. Petrachkov DV. The new complex method of treatment central retinal vein and branch of retinal vein occlusion. Bulletin of Siberian Medicine. 2008;7(1): 99–101. (In Russ.) https://doi.org/10.20538/1682-0363-2008-1-99-101.

40. Razumovskaya AM, Razumovskiy MI, Korovyanskiy YA. Сomparative Efficiency of Use of Methylethylpyridinol by the Endonasal Electrophoresis and Parabulbar Injections at the Chorioretinal Dystrophy. Oftalmologiya. 2017;14(3):268–273. https://doi.org/10.18008/1816-5095-2017-3-268-273.

41. Borisova NA, Rakhimkulov AS, Khaziakhmetov RM, Rizvanova AS, Avertsev GN. Endonasal electrophoresis with ceruloplasmin, cerebrolyzate and tanakan in cerebrovascular diseases. Nizhegorodskii Meditsinskii Zhurnal. 2003;(2):111–114. (In Russ.) Available at: https://elibrary.ru/xwogn.

42. Razumovskaya AM, Razumovsky MI, Koroviansky YuA, Razumovsky ES. Еstimation of Therapeutic Effect of Endonasal Electrophorosis with Methylethylpyridinol in Partial Optic Nerve Atrophy. Oftalmologiya. 2018;15(2): 219–224. (In Russ.) https://doi.org/10.18008/1816-5095-2018-2-219-224.

43. Povaliaeva DA, Egorov VV, Smoliakova GP, Danilova LP. Clinical Aspects of Using of Etiotropic Immunotherapy in Complex Treatment of Patients with Acute Optic Neuritis Associated with Herpesvirus Infection. Oftalmologiya. 2018;15(1):80–86. (In Russ.) https://doi.org/10.18008/1816-5095-2018-1-80-86.

44. Francisco BM, Salvador M, Amparo N. Oxidative stress in myopia. Oxid Med Cell Longev. 2015:750637. https://doi.org/10.1155/2015/750637.

45. Shih YF, Horng IH, Yang CH, Lin LL, Peng Y, Hung PT. Ocular pulse amplitude in myopia. J Ocul Pharmacol. 1991;7(1):83–87. https://doi.org/10.1089/jop.1991.7.83.

46. Бржеский ВВ, Воронцова ТН, Догадова ЛП, Жукова ОВ, Иомдина ЕН, Маркова ЕЮ и др. Миопия: клинические рекомендации. М.; 2024. 87 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/109_2.

47. Tarutta EP, Iomdina EN, Tarasova NA, Markosyan GA, Maksimova MV. Complex approach to the prevention and treatment of progressive myopiain school children. RMJ Clinical Ophthalmology. 2018;18(2):70–76. (In Russ.) https://doi.org/10.21689/2311-7729-2018-18-2-70-76.

48. Volchegorskii IA, Sinitskii AI, Miroshnichenko IYu, Rassokhina LM. The effect of 3-oxypyridine and succinic acid derivatives on in vitro activity of monoamine oxidase. Pharmaceutical Chemistry Journal. 2018;52(1):3–7. (In Russ.) https://doi.org/10.30906/0023-1134-2018-52-1-3-7.

49. Гундорова РА, Ромащенко АД, Цыпин АБ, Смирнов ЛД. Антигеморрагическое средство «Эмоксипин» для рассасывания внутриглазных кровоизлияний. Патент SU1537247A1, 23.01.1990. Режим доступа: https://yandex.ru/patents/doc/SU1537247A1_19900123.

50. Mokhammad I, Cherkasov IS. The efficacy of treating patients with intraocular hemorrhages with emoxypin. Journal of Ophthalmology (Ukraine). 1990;(1):29–30. (In Russ.) Available at: https://pubmed.ncbi.nlm.nih.gov/2280919.

51. Guskova TA, Liberman SS. The use of the drug Emoksipin in diseases of the eye. Farmateka. 1999;(6):25–26. (In Russ.) Available at: http://elib.fesmu.ru/Article.aspx?id=46238.

52. Podkolzin AA, Megreladze AG, Dontsov VI, Arutyunov SD, Mrikaeva OM, Zhukova EA. System of antioxidant defense of the organism and aging. Prophylaxis of Aging. 2000;(3):3–6. (In Russ.) Available at: https://medi.ru/info/8441/.

53. Макогон СИ, Макогон АС, Момот АП. Способ профилактики прогрессирования первичной открытоугольной глаукомы. Патент RU 2705040 C1 11.01.12019. Режим доступа: https://yandex.ru/patents/doc/RU2705040C1_20191101.

54. Пономарева ЕЮ, Руднева ЛФ, Пономарева МН, Борщенко ЯА, Коновалова НА, Патрикеев ИМ, Савина ЕЕ. Способ лечения патологии суммарной слезопродукции у пациентов с ревматоидным артритом. Патент RU 2677190 С1, 15.01.2019. Режим доступа: https://yandex.ru/patents/doc/RU2677190C1_20190115.